29754-58-3

Usage

Uses

Used in Pharmaceutical Research:
3-CARBOMETHOXY-4-HYDROXYPHENYLGLYOXAL HYDRATE is used as a key intermediate for the synthesis of various pharmaceuticals and bioactive compounds, contributing to the development of new drugs and therapies.
Used in Organic Synthesis:
3-CARBOMETHOXY-4-HYDROXYPHENYLGLYOXAL HYDRATE is used as a reagent in the synthesis of complex organic molecules, facilitating the creation of diverse chemical structures for research and development purposes.
Used in Neurological Disorder Treatment:
3-CARBOMETHOXY-4-HYDROXYPHENYLGLYOXAL HYDRATE is studied for its potential therapeutic applications in the treatment of neurological disorders, offering a promising avenue for medical advancements in this field.
Used in Cancer Treatment:
3-CARBOMETHOXY-4-HYDROXYPHENYLGLYOXAL HYDRATE is explored for its potential in treating cancer, with ongoing research aimed at understanding its mechanisms of action and efficacy in combating various types of cancer.
Used in Medicinal Chemistry and Drug Discovery:
3-CARBOMETHOXY-4-HYDROXYPHENYLGLYOXAL HYDRATE is utilized as a valuable chemical building block in the field of medicinal chemistry and drug discovery, playing a crucial role in the development of innovative pharmaceuticals and therapeutic agents.

InChI:InChI=1/C10H8O5.H2O/c1-15-10(14)7-4-6(9(13)5-11)2-3-8(7)12;/h2-5,12H,1H3;1H2

Upstream product

• 36256-45-8 3-carbomethoxy-4-hydroxy-α-bromoacetophenone 
• 580-02-9 methyl acetylsalicylate 
• 16475-90-4 estere metilico dell'acido 5-acetilsalicilico 

Downstream Products

• 27566-12-7 2-Hydroxy-5-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-benzoic acid methyl ester 
• 18559-94-9 Salbutamol 
• 48224-49-3 C₂₂H₃₂N₂O₆ 
• 321708-41-2 C₂₅H₃₀N₂O₆ 
• 321708-31-0 C₂₆H₃₂N₂O₆ 
• 41640-58-8 C₂₈H₃₆N₂O₆ 
• 321708-23-0 C₃₁H₄₆N₂O₆ 
• 321708-25-2 C₂₆H₃₈N₂O₆ 
• 1355183-61-7 C₂₃H₃₄N₂O₆ 
• 1355183-45-7 C₂₆H₃₂N₂O₄ 

Relevant academic research and scientific papers

A chromatography-free synthesis of racemic salbutamol hemisulfate

Our efforts to achieve an efficient synthesis of racemic salbutamol hemisulfate are described. The selected chemical route starts from commodity chemicals and allows the generation of salbutamol hemisulfate in 5 steps and 44% overall yield without any purification by column chromatography. The reaction sequence has been optimized to provide the title compound using robust procedures. Emphasis on reproducibility and experimental simplicity drove the work described herein.

A multivalent approach to the discovery of long-acting β2- adrenoceptor agonists for the treatment of asthma and COPD

A multivalent approach was applied to the design of long-acting inhaled β2-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting β2-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection.

β2-adrenergic receptor agonists

The present invention is directed to multibinding compounds which are β2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such asthma, bronchitis, and the like. They are also useful in the treat

β2- adrenergic receptor agonists

The present invention is directed to multibinding compounds which are β2 adrenergic receptor agonists and are therefore useful in the treatment and prevention of respiratory diseases such asthma, bronchitis, and the like. They are also useful in the treatment of nervous system injury and premature labor.